131I Therapy for Elevated Thyroglobulin Levels
- 1 April 1997
- journal article
- review article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 7 (2) , 273-276
- https://doi.org/10.1089/thy.1997.7.273
Abstract
Assuming that the fractional uptake is the same, both after the administration of a diagnostic and a therapeutic activity, 131I uptake too low to be detected with 2-5 mCi may become detectable after the administration of 100 mCi. This should be performed routinely in patients with thyroglobulin levels above approximately 5 ng/mL during L-Thyroxine (LT4) treatment or 10 ng/mL off LT4 treatment for three main reasons: 1) in 80% of these patients, a post-therapy 131I total body scan showed foci of uptake in the neck or at distant sites, whereas in the other patients, metastases emerged clinically some years later; 2) 131I is not the only treatment modality, and, for instance, lymph node metastases may warrant further surgery; and 3) from a dosimetric point of view, the relevant parameter is the concentration of 131I, i.e., the ratio between the uptake and the mass of functioning tissue: a low uptake in a small metastasis may result in a higher 131I concentration than a higher uptake in a much larger metastasis.Keywords
This publication has 4 references indexed in Scilit:
- Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scanJournal of Clinical Endocrinology & Metabolism, 1995
- Cancer risks in thyroid cancer patientsBritish Journal of Cancer, 1991
- DIAGNOSTIC VALUE OF A SINGLE SERUM THYROGLOBULIN DETERMINATION ON AND OFF THYROID SUPPRESSIVE THERAPY IN THE FOLLOW‐UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCERClinical Endocrinology, 1985
- The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancerThe American Journal of Medicine, 1981